Physician profile
Leon Weinstein
NPI 1265511752
$8,427.35
in general payments reported to CMS, 2019-2025
42 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $918 · 2021: $1,013 · 2022: $1,643 · 2023: $1,122 · 2024: $1,261 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.50 | 2019-2025 | |
| Amgen INC. | $1,225.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,203.81 | 2019-2024 | Airsupra, Lokelma, Farxiga |
| Novo Nordisk INC | $775.70 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $528.26 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $262.87 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $244.01 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $240.99 | 2022-2025 | Dupixent |
| Cequr Corporation | $217.28 | 2022-2023 | Cequr Simplicity |
| Scilex Pharmaceuticals INC. | $202.10 | 2022 | |
| Amarin Pharma, INC. | $196.13 | 2019-2021 | |
| Astellas Pharma US INC | $188.83 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $155.25 | 2019-2020 | |
| Allergan, INC. | $150.88 | 2019-2020 | |
| Intuity Medical INC | $150.01 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.